Aegis Maintains Navidea Biopharma (NAVB) at 'Hold'; NDA Approval Positive, but Lymphoseek Needs to Gain Traction

Navidea Biopharma (NAVB) Appoints Rick Gonzalez as CEO

October 15, 2014 8:04 AM EDT

Navidea Biopharma (AMEX: NAVB) announced that Rick Gonzalez has been appointed Chief Executive Officer effective October 13, 2014. Mr. Gonzalez has more than 20 years of experience in the pharmaceutical industry, and most recently served as Vice President, Global Operations at Spectrum Pharmaceuticals, a biotechnology company focused in oncology and hematology.e)

It is with great pleasure that Navidea welcomes Rick Gonzalez as the new Chief Executive Officer, said Gordon Troup, Chairman of the Board of Navidea. Rick brings an impressive depth of global commercial, operational and leadership experience in the biotechnology field including oncology and radiotherapy,... More

Navidea Biopharma (NAVB) Granted FDA Approval for Expanded Use of Lymphoseek

October 15, 2014 7:05 AM EDT

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek injection for lymphatic mapping in solid tumors and adding Sentinel Lymph Node detection for... More

Navidea Biopharma (NAVB): FDA Approves Expanded Use of Lymphoseek

October 15, 2014 7:05 AM EDT

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek® (technetium Tc 99m tilmanocept) injection for lymphatic mapping in solid tumors and adding Sentinel Lymph Node detection for breast cancer and melanoma to the approved indications. Lymphoseek is now indicated for:

Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this... More